ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,408.90
0.36%
S&P ASX All Technology
3,893.00
0.20%
Brent Oil
77.035
-0.19%
US Dollar vs AUD
1.59013
0.42%
Bitcoin
100,231.04
-2.37%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Inozyme Pharma Inc (INZY) Share Price

Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

NASDAQ
1.41
0.09
(6.82%)
Closed 27 January 8:00AM
Delayed by 15 minutes
1.4399
0.0299
(2.12%)
After Hours: 11:02AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.4399
Bid
1.39
Offer
1.44
Volume
902,984
1.32 Day's Range 1.485
1.29 52 Week Range 7.795
Market Cap
92.499M
Previous Close
1.32
Open
1.32
Last Trade
190
@
1.4399
(formt)
Last Trade Time
Financial Volume
US$ 1,280,915
VWAP
1.4185
Average Volume (3m)
735,762
Shares Outstanding
64,240,198
Dividend Yield
-
PE Ratio
-1.26
Earnings Per Share (EPS)
-1.11
Revenue
-
Net Profit
-71.17M

About Inozyme Pharma Inc

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.inozyme.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was US$1.32. Over the last year, Inozyme Pharma shares have traded in a share price range of US$ 1.29 to US$ 7.795.

Inozyme Pharma currently has 64,240,198 shares in issue. The market capitalisation of Inozyme Pharma is US$84.80 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -1.26.

Ask ADVFN Intelligence (AI)

INZY Latest News

More News

Form 8-K - Current report

11 January 2025
Edgar (US Regulatory)

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and...

11 January 2025
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

10 December 2024
Edgar (US Regulatory)

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

28 November 2024
GlobeNewswire Inc.

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

12 November 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

09 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 November 2024
Edgar (US Regulatory)

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in...

06 November 2024
GlobeNewswire Inc.

Form 8-K - Current report

25 October 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.05994.340579710141.381.441.2912305971.33696754CS
4-1.6001-52.63486842113.043.181.299403861.87114393CS
12-2.8701-66.59164733184.314.64011.297357622.56290722CS
26-4.1801-74.37900355875.626.241.294581723.35717331CS
52-3.2001-68.96767241384.647.7951.294872094.47712637CS
156-5.2001-78.31475903616.647.980.9914932384.15526284CS
260-16.4901-91.969325153417.9331.64990.9913499415.04958295CS

INZY - Frequently Asked Questions (FAQ)

What is the current Inozyme Pharma share price?
The current share price of Inozyme Pharma is US$ 1.4399
How many Inozyme Pharma shares are in issue?
Inozyme Pharma has 64,240,198 shares in issue
What is the market cap of Inozyme Pharma?
The market capitalisation of Inozyme Pharma is USD 84.8M
What is the 1 year trading range for Inozyme Pharma share price?
Inozyme Pharma has traded in the range of US$ 1.29 to US$ 7.795 during the past year
What is the PE ratio of Inozyme Pharma?
The price to earnings ratio of Inozyme Pharma is -1.26
What is the reporting currency for Inozyme Pharma?
Inozyme Pharma reports financial results in USD
What is the latest annual profit for Inozyme Pharma?
The latest annual profit of Inozyme Pharma is USD -71.17M
What is the registered address of Inozyme Pharma?
The registered address for Inozyme Pharma is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Inozyme Pharma website address?
The website address for Inozyme Pharma is www.inozyme.com
Which industry sector does Inozyme Pharma operate in?
Inozyme Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

INZY Discussion

View Posts
tj9938 tj9938 2 months ago
Taking a beating this week. 
👍️0
Monksdream Monksdream 5 months ago
INZY under $6
👍️0
AJ Freely AJ Freely 1 year ago
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 2 years ago
INZY new 52 week high
👍️0
INFINITI INFINITI 2 years ago
Loading
👍️0
Jess070283 Jess070283 2 years ago
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 2 years ago
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 2 years ago
Quietest board out there
👍️0
ErnieBilco ErnieBilco 3 years ago
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 3 years ago
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 3 years ago
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 3 years ago
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 3 years ago
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 3 years ago
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 3 years ago
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 3 years ago
PT > 33.00
👍️0
crudeoil24 crudeoil24 3 years ago
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

Your Recent History

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads